Table 5.
Femur | Tibia | ||||||||
---|---|---|---|---|---|---|---|---|---|
Pb | Cd | Pb | Cd | ||||||
Treatment Group | N | Avg | SD | Avg | SD | Avg | SD | Avg | SD |
Control | 5 | 0.16* | 0.14 | ND** | - | 0.16 | 0.06 | ND | - |
3 mM Pb | 12 | 287 | 45 | ND^ | - | 216 | 51 | ND | - |
300 μM Cd | 11 | 0.13^^ | 0.01 | 0.27 | 0.03 | 0.18 | 0.04 | 0.23 | 0.03 |
300 μM Cd + 3 mM Pb | 9 | 236 | 24 | 0.26 | 0.02 | 207 | 23 | 0.21 | 0.02 |
All five samples run in control groups showed levels of Pb were detectable and above the limit of detection of 0.05 mg/kg
All five samples in control groups showed levels of Cd were below the limit of detection of 0.05 mg/kg.
Two femur and tibia samples run in Pb treatment groups showed levels of Cd were below the limit of detection of 0.05 mg/kg. Results were similar to control levels.
Two femur and tibia samples run in Cd treatment groups showed levels of Pb were detectable and above the limit of detection of 0.05 mg/kg. Results were similar to control levels.